论文部分内容阅读
35例心衰患儿分为常规治疗组15例及苯那普利加常规治疗组20例,于治疗前后对照检测血管紧张素Ⅱ(Ang Ⅱ)、血管紧张素转换酶(ACE)、内皮素(ET)、循环内皮细胞(CEC)、心胸比率、射血分数、收缩时间间期、小轴缩短率及左室重量指教。结果各项指标均有统计学意义,苯那普利组疗效明显优于常规组。表明心衰时肾素—血管紧张素系统过度激活,ACE活性增加。Ang Ⅱ生成增多,ET及CEC增加,致心肌损害,引起心肌重构,形成心衰恶性循环,而血管紧张素转换酶抑制剂(ACEI)可抑制Ang Ⅱ生成及改善内皮功能,从而阻断心肌重构和改善心衰预后。
Thirty-five children with heart failure were divided into routine treatment group (n = 15) and benazepril plus conventional treatment group (n = 20). Before and after treatment, the levels of angiotensin Ⅱ, angiotensin converting enzyme (ACE) ET, CEC, cardiothoracic ratio, ejection fraction, systolic time, small axis shortening and left ventricular mass. Results The indicators were statistically significant, benazepril group was significantly better than the conventional group. Renal-angiotensin system is over-activated and ACE activity is increased during heart failure. Ang Ⅱ production increased, ET and CEC increased, causing myocardial damage, causing myocardial remodeling, the formation of a vicious circle of heart failure, and angiotensin-converting enzyme inhibitor (ACEI) can inhibit Ang Ⅱ production and improve endothelial function, thus blocking the myocardium Reconstruction and improvement of heart failure prognosis.